Skip to main content

Establishing a milestone in our journey towards transforming healthcare from reactive to proactive, Kaligia Biosciences has received an encouraging nudge from US Food and Drug Administration. The FDA approval to begin clinical testing was granted in September this year allowing us to introduce our non-invasive glucose monitoring system to participating hospitals.

Kaligia plans on furthering their mission by partnering with hospitals in Florida to carry out clinical testing to perfect our good health platform before unraveling the product to an open market.

Leave a Reply